Table 2. Most frequently deregulated lncRNAs in malignant B-cells.
| lncRNA(s)/alias | Disease type | Genome location | Functiona | Molecular mechanism | References |
|---|---|---|---|---|---|
| BALR-1/c14orf132 | B-ALL | 14q32.2 | U | Not described | [35] |
| BALR-2 | B-ALL | 7q21.2 | U | Inhibition of genes downstream of the glucocorticoid receptor (FOS, JUN, BIM) | [35] |
| BALR-6 | B-ALL | 3p24.3 | U | Possible regulation of the transcriptome downstream of SP1 | [35, 36] |
| LINC00958/LOC1506305 | B-ALL | 11q15.2 | U | Not described | [35] |
| DLEU2 | CLL, MM | 13q14.3 | TS | NF-kB activation. Host of miR-15a/16-1 cluster targeting BCL2 | [42–48, 111] |
| NEAT1 | CLL | 11q13.1 | TS | Induced by p53 | [49, 52, 53] |
| lincRNA-p21/TP53COR1 | CLL, DLBCL | 17p13.1 (mouse) 6p21.2 (human) | TS | Induced by p53. Functionally linked to Cyclin D1, CDK4 and p21 in human DLBCL tissues | [49–51, 88] |
| MIAT | CLL | 22q12.1 | O | Constitution of a regulatory loop with OCT4 | [54–57] |
| ZNF667-AS1/lnc-AC004696.1-1 | CLL | 19q13.43 | U | Not described | [60, 61] |
| BM742401 | CLL | 18q11.2 | TS | Not described | [58, 59] |
| BIC | CLL | 21q21 | OnP | Host of miR-155-5p and miR-155-3p | [29–31, 132, 133] |
| lnc-IRF2-3 | CLL | 4q35 | U | Not described | [61] |
| lnc-KIAA1755-4 | CLL | 20q11.23 | U | Not described | [61] |
| GAS5 | MCL, DLBCL, MM | 1q25.1 | TS | Required for the inhibitory effects of mTOR antagonists. Regulated by mTOR pathway | [65–73, 111, 134] |
| MALAT1 | MCL, MM | 11q13 | O | SP1 recruitment to the promoter of LTBP3 gene regulating the bioavailability of TGF-β. | [74–76, 110–114] |
| RP11-625 L16.3 | FL | 12 | U | Not described | [80] |
| LOC283177 | DLBCL | 11q25 | U | Not described | [85] |
| lnc-RP11-211G3.3.1-1 | DLBCL | 3q27.3 | U | Not described | [84] |
| LUNAR1 | DLBCL | 15q26.3 | O | Regulated by NOTCH1. Enhancement of IGF1R mRNA expression | [86, 87] |
| PEG10 | DLBCL | 7q21.3 | O | Activated by c-MYC | [89–91] |
| HULC | DLBCL | 6p24.3 | O | Not described | [92–95] |
| HOTAIR | DLBCL | 12q13.13 | O | Regulation of the PI3K/AKT/NF-κB pathway | [96] |
| MINCR | BL | 8q24.3 | U | Induced by MYC | [103] |
| MEG3 | MM | 14q32.2 | TS | Interaction with p53. Regulation of P53 gene expression. Enhancement of the expression of BMP4 gene in MM-MSCs. | [115–117] |
| TUG1 | MM | 22q12.2 | O | PRC2 binding to repress cell-cycle regulation genes. Induced by p53 | [112, 118] |
| lnc-SENP5-4/NCBP2 -AS2 | MM | 3q29 | U | Not described | [111] |
| lnc-CPSF2-2 | MM | 14q32 | U | Not described | [111] |
| lnc-LRRC47-1/TP73-AS1 | MM | 1p36 | U | Not described | [111] |
| lnc-ANGPTL1-3 | MM | 1q25 | U | Not described | [111] |
| lnc-WHSC2-2 | MM | 4p16.3 | U | Not described | [111] |
Abbreviations: B-ALL, B acute lymphoblastic leukemia; CLL, chronic lymphocytic leukemia; BL, Burkitt lymphoma; DLBCL, diffuse large B-cell lymphoma; FL, follicular lymphoma; MCL, mantle cell lymphoma; MM Multiple Myeloma.
a U = Uncharacterized; O = Oncogene; TS = Tumor Suppressor; OnP = Oncomir Progenitor